DENISE VIEKMAN: Open Payments
NPI 1295789329 · PORTLAND, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,097 in 142 payments from 19 companies in 2025. Trend: 2023 $3,559 · 2024 $3,607 · 2025 $4,097
Food & beverage: $4,044Education: $53
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 35 | $1,300 |
| Regeneron Healthcare Solutions, Inc. | 24 | $851 |
| GENZYME CORPORATION | 14 | $468 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $298 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $273 |
| GlaxoSmithKline, LLC. | 14 | $210 |
| Novartis Pharmaceuticals Corporation | 12 | $171 |
| Amgen Inc. | 4 | $100 |
| Verona Pharma, Inc. | 2 | $53 |
| SANOFI-AVENTIS U.S. LLC | 1 | $53 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, NEFFY, AIRSUPRA, CUVITRU, NUCALA, BREZTRI.
Industry payments across ME — which companies pay providers there.
